Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I bought more!
The SP will skyrocket once we have a better idea of how many new LPs are going to be in the market.
They are all going to need genetics on a regular basis, and testing is going to be huge. Since THC is permitted to sell, the new LPs are going to be using them to get their products to market, depending on how cannabis will be retailed province by province.
I have been holding for a long time now, checking on the SP from time to time. THC is so undervalued, or other LPs are overvalued. I don't believe it's the latter. Many investors are holding, so there's not a lot of selling going on, which is keeping the price low, that's why I bought more. Buying THC is very good deal now.
One more thing I would like to add is that THC is the only LP not holding any debt, they have assets and $$$$ in the bank.
Whoever is telling you not buy this stock is only trying to short. THC is selling for a very good deal right now. And they have set themselves up to becoming one of the big players in the industry due to the unique services they can provide to LPs and the general public.
THC is also licensed for everything. They are the only LP that is licensed for everything.
It will be over $1.20 soon, and here's why:
-GEM believes that they are getting a discount at $1.20, meaning that they obviously understand the true value of the company. MJ stocks are undervalued, and THC is the most undervalued.
-$10 million is not chump change. I know GEM, and they are very successful at picking winners. They are going to turn that $10 million into $200 million in less than 2 years. They have happy clients.
Check out the press release bellow. It's all in the details!
Previous
THC Announces $10,000,000 Capital Commitment
VANCOUVER, March 16, 2017
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITU TE A VIOLATION OF U.S. S ECURITIES LAWS./
THC.CSE
THCBF – OTC
TFHC.F
VANCOUVER, March 16, 2017 /CNW/ – THC BioMed Intl Ltd. (“THC” or the “Company”) (CSE:THC) announces that it has entered into a capital commitment agreement (the “Capital Commitment”) with GEM Global Yield Fund LLC SCS (“GEM”) for a $10 million Capital Commitment from GEM to invest into THC. Proceeds raised from the investment will be used for working capital and general corporate purposes, particularly to acquire Clone Shipper LLC and support the Company’s ongoing activities, development and expansion as a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”).
THC has the right to draw down under the Capital Commitment for a term of 2 years. Common shares will be issued to GEM at a price per share equal to the higher of the floor price set by THC and a 10 per cent discount to the market price of the common shares based on the immediately preceding 15-day volume weighted average price at for the acceptance period. Each draw down is subject to certain market out rights of GEM and approval of the CSE. GEM will hold freely trading common shares of the Company through a share lending facility provided by certain current shareholders.
THC will pay to GEM a commission fee of $225,000 upon the earliest of the closing of a private placement (in an amount equal to 15% of the proceeds of placements until the full amount of the fee is paid), 18 months from the date of the Capital Commitment or a change of control of THC. This fee will be payable by THC at the 18-month date even if it doesn’t make any demands on the Capital Commitment. If, however, GEM fails to invest pursuant to the terms of the Capital Commitment, the fee will not be payable by THC. THC may elect to pay the commitment fee in cash or stock (subject to CSE approval).
As part of the transaction, THC has agreed to issue 6,635,000 common share purchase warrants to GEM, subject to the terms and conditions of the Capital Commitment. The warrants have an exercise price equal to the greater of $1.20 and the Market Price of the Common Shares on the date of the issuance of the Warrants. The warrants will have an exercise period of five years. The warrant exercise price is subject to repricing to 105% of the market price in the event that THC’s market price is less than 90% of the Warrant exercise price on the first anniversary of the date of the Capital Commitment. The repricing must be done in accordance with the rules of the CSE. If the Company does not issue the 6,635,000 warrants within 18 months of the initial execution of the Agreement, the Company shall pay GEM 8% of the original face value of any unissued warrants.
All references to currency are in Canadian dollars.
About GEM
Global Emerging Markets (www.gemny.com) was founded in 1991. GEM is a USD 3.4 billion investment group having completed 370 transactions in 70 countries. The firm is an alternative investment group that manages a diverse set of investment vehicles across the world. Each investment vehicle has a different degree of operational control, risk-adjusted return and liquidity profile. Our family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities (PIPEs) and select venture investments. GEM’s funds include: CITIC-GEM Fund (matured in December 2015), Kinderhook Industries (GP and LP non-voting stakes), GEM Global Yield Fund LLC SCS, GEM India and VC Bank/GEM Mena Fund (GEM exited both its GP and LP stakes in these funds in 2015 and 2010 respectively).
About THC
THC is a Licensed Producer under Canada’s ACMPR. THC’s vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.
Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that (a) the investment from GEM will be used for the Clone Shipper acquisition and support the Company’s ongoing activities, development and expansion as a Licensed Producer, (b) THC will draw down $10,000,000 in investment from the Capital Commitment (c) THC will issue the warrants as described in this press release, (d) as the medical marijuana industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis and (e) THC will be in the forefront of this rapidly growing industry. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
I know some of you will ask how I came to those numbers. Here's my explanation:
The $80,000 saved is from the 4000 clones they would have cut themselves at $20/clone.
In order to cut 4000 clones, the mother room would have to be at least 600 sq ft, and that would be squeezing the mothers in. Realistacally you would need 1000 sq. ft. Then you would need at least 2000 sq. ft for the nursery that would not be used after the 10 to 12 days required for the clones to root, a room that would not be in use for 6 weeks at a time (most of the year). That 3000 sq. ft would produce at least $270,000/ year in marijuana (could actually produce $400,000).
I haven't accounted for the manpower to cut, plant and care for the clones, which would obviously increase costs.
I hope this helps you understand the numbers.
Some of you had questions about buying clones versus LPs cutting them themselves.
The space that's used for mother plants, cutting clones, and the clone nurseries would be in better use to grow marijuana. The initial savings would not outweigh the money produced by growing marijuana.
First you would need a veg room for the mother plants that would produce good clones. In order to cut the thousands of clones that some LPs would need, it would have to be a large veg room. Then you would need large a nursery for those thousands of clones. They would be in the nursery for 10 to 12 days until they make roots, then you would need manpower to plant those thousands of clones. Then the nursery would not be in use for at least 6 weeks until new clones are needed and cut, to redo the whole process again. The loss of revenue and the manpower used would not make it worth it for any LP to cut their own clones. The space used for in the nursery and mother room could produce an extra 150 lbs/year, which is worth at least an extra $270,000/year. Cutting their own clones would only save them less than $80,000 when you factor in all the costs. Like any business person, I would rather make an extra $270,000 than save $80,000.
Someone has to supply the LPs with clones. THC is best placed to do so. There are more than 100 applicants who will eventually get licensed by Health Canada. They are all going to need clones, and they are all going to need a consistent and reliable source. THC is that reliable source.
They are going to make me a lot of $$$$!!!!
This bottleneck in genetics (clones and seeds) is good for THC:
Here's the article from Lift:
The other cannabis genetics bottleneck
Along with home growers, new licensed producers are finding it challenging to find a legal supply of seeds or clones that satisfies their needs.
By David Brown
November 29, 2016
While access to legal sources of starting materials is a known issue for patients in Canada, the ability for Health Canada-regulated licensed producers to source seeds and clones is a lesser known issue within the industry.
Early-licensed, established producers have been given access to sources of genetics that those licensed later on, in a more than three-year-old program, haven’t been given the same access to.
When Health Canada introduced the Marihuana for Medical Purposes Regulations (MMPR) in June 2013, it allowed — for the first time in Canada — the commercial retail production and sale of cannabis for medical purposes. Prior to this, medical cannabis in Canada was regulated under the Marihuana Medical Access Regulations (MMAR), but production was limited to personal or designated growers (in August of this year the government replaced the MMPR with the Access to Cannabis for Medical Purposes Regulations (ACMPR).
Up until March 31, 2014, those licensed by Health Canada to produce cannabis could transfer genetics from approved Health Canada producers under the previous MMAR regime. No retail sales were regulated through this regime. Nonetheless, it blossomed into an enormous cottage industry of medical cannabis growers and breeders, giving birth to strains unique to Canada, as well as bringing in genetics from overseas.
Many of the first licensed producers (LPs) sourced their genetics this way, and many of the existing strains available within Canada’s legal medical cannabis regime to authorized patients come from these MMAR sources. Some of these represent unique options developed in part by Canadian growers under Canada’s old MMAR. Two of the early licensed LPs, Tweed and Mettrum, even had a shipment of MMAR genetics seized by RCMP in the final moments of the exemption, in what was described as a miscommunication.
Purple Lightning clones start their journey to flower
Purple Lightning clones start their journey to flower at Broken Coast on Vancouver Island.
In addition to sourcing starting material from these MMAR growers, LP’s could register to import cannabis from overseas sources, but these options were limited and the process can be very complicated.
Health Canada’s rules for importing genetics can be complex, as there are only a handful of countries in the world with a regime that matches these requirements.
For some time, producers were able to source seeds from various companies in the Netherlands. But a recent change in government, say some new producers, has meant the Dutch government won’t authorize exports for any company other than Bedrocan BV. Bedrocan BV has traditionally only supplied genetics for their Canadian partner, Bedrocan Canada.
As the ACMPR grows and more producers are approved for sale, this issue will only become bigger. Consumers can easily buy seeds and even clones online from illegal sources with little delay, but licensed producers are at the mercy of a market with a severe bottleneck that benefits the handful of producers first licensed. For both producers and the patients they supply to be properly served, these gaps need to be addressed. Legalization for non medical purposes will likely present similar challenges.
Marc Ripa, the owner of AB Labs, a licensed producer in Ontario who received their cultivation license on Oct 21, says there needs to be a change in the rules to allow new LPs the same opportunity to source from approved MMAR growers in the same way that the first producers were able to.
“Every company, after going through the process we’ve gone through, should be entitled to obtain those materials” says Ripa.
According to the owner, AB Labs was application number eight and were in pre-license inspection for R&D exemption in June 2013. They were growing under the previous MMAR and could have imported genetics themselves, had they received their license prior to the March 31 2014 deadline. Until they can source genetics, AB Labs will not be able to begin cultivation.
screen-shot-2016-11-28-at-8-12-25-pmRipa says that communication with Health Canada has noticeably improved over the last year and that he expects an update from them that will allow him to source genetics soon. He emphasizes he isn’t complaining. He’s kept his head down, he says, focusing on building an excellent facility over the past two years, but it’s still important for a fair market to give all producers the same opportunities.
Another newer producer who hopes to address this bottleneck is Kelowna’s THC Biomed, licensed for production in February of this year and licensed to sell genetics to other LPs on Oct 17. Jon Miller, the company’s President and CEO, says they expect to have starting materials available for consumers very soon.
The company lists 27 different strains on its website. Miller says his aim is to increase variety and access for patients and producers, not limit.
“We’re ready to supply patients, and patients need to be supplied,” says Miller. “THC Biomed is one of the only companies who has always sought to supply genetics. Other producers talk about proprietary strains and want to keep genetics to themselves, whereas we went in the opposite different direction and have a whole section dedicated to that.”
Propagation Tray filled with clones (cuttings) that will spend 2 weeks here before continuing their journey to becoming production plants
Propagation Tray filled with clones (cuttings) that will spend 2 weeks here before continuing their journey to becoming production plants
Like Ripa and Miller, Jeanette VanderMarel and Scott Skinner also initially applied for a license to produce cannabis from Health Canada in mid 2013. The co-owners of Ontario’s the Green Organic Dutchman received approval to cultivate in August of this year, and approval to transfer genetics to other licensed producers shortly after. VanderMarel, who had grown under the MMAR, was able to work with a producer licensed prior to the deadline to secure her own genetics. In October they received approval to supply genetics to other producers.
Although the last three years have been a considerably arduous waiting game, like Ripa, Skinner notes that the last six months or so have seen a marked improvement in communications from Health Canada.
“We’ve found that things have moved along much quicker since about February of this year once the new government had the ability to organize the Office of Medical Cannabis,” says Skinner. “I think they’ve been much more responsive to our requests, as evidenced by our now being licensed.”
Duncan, BC-based licensed producer United Greeneries has announced they have received an import permit from Health Canada for 1kg of cannabis seeds.
The import permit will allow the company to begin starting the production of rooted clones in their Vancouver Island facility from seed by mid January, says Andreas Gedeon, Managing Director and CEO of MMJ PhytoTech. United Greeneries is the Canadian subsidiary of MMJ-PhytoTech, based in Australia.
Gedeon says United Greeneries wants to specialize in providing starting materials for both consumers as well as other licensed producers. By April 2017, the goal is to have 30 different varieties of rooted clones available for sale. This will allow consumers and retailers access to more variety, he says, and allow producers to outsource propagation entirely, focusing on flower and or oil production.
“Our facility in Duncan is going to be focusing on the production of rooted cuttings, in high volumes, that we will make available to both individuals under the ACMPR as well as to other LPs. For other LPs we will supply high volumes of rooted cuttings on an ongoing production level, so they can completely outsource the propagation of plant material to us.”
Gedeon says the intention is to be able to ship clones overnight, anywhere in Canada, with a consumer price of about $15-20 each, plus taxes, shipping, etc.
Ideally, the government is able to forge a relationship with other legal nations like the Netherlands, Israel, Germany, Uruguay, Columbia, and Australia that will satisfy Health Canada while also satisfying the demands of the market. There are numerous commercial seed companies out there, and much of the problem in licensed producers accessing them is the gap in legality between jurisdictions and nations in the end days of prohibition.
Ideally, the Canadian government can learn from these issues by transitioning formerly illicit products into a regulated regime for the medical market as it moves towards legalizing for a nonmedical market, creating a functional system — a more level playing field, which will certainly be as crucial to establishing a functional nonmedical system as it will be to creating a functional medical one
You are right and here's why: Currently, there are more than 200 applicants to become licenced producers in Canada. If they regularly supplied a fraction of those applicants, they are going to do around $150 million in sales every year. That's without any growth. When weed get legalised in Canada, which is going to happen in a very short term, relatively speaking, many other Licensed Producers are going to pop up. From micro grows to big cannabis producers, they are going to need clones on regular basis. Then there are the US states that have legalised for medical and rec use. THC is an international company;they will be marketing themselves to producers in legalised territories. Based on those FACTS, you can easily triple to quadruple the $150 million based on those factors. That adds a lot of value to long term investors. That's only in clone sales.
THC also has a testing facility. If they test a fraction of the new applicants harvested cannabis and extracts, they are looking at another $70 million is sales every year without any growth. Based on the facts I listed above,you can easily triple to quadruple that $70 million sales every year.
With the space they have, they are going to produce about $125 million worth of product every year, this is nit counting any growth. There will be a demand for more product, so they will end up with more real estate. There will be growth on those numbers.
Where they will initially make the least money will be be in R&D. There will be a maximum of $1 million per year from government agencies for research. The Development side could potentially lead to new products that could be extremely profitable.
This is the most undervalued stock in MMJ. With minimal space, they are going to be having the same over $200 million sales that Canopy plans on doing wih legal recreational MJ. THC is a $3-$4 billion company valued at only $100 million. When investors see and understand the long term plans of this company, the SP is going to shoot right up. Be glad you got it for cheap. Hold for the long. It will pay off big time. If you can afford to buy more and hold for the long, do it.
I have pulled out my calculator for this.
THC's business plan is so obvious, a baby can figure it out.
They intend to sell clones (by the thousands - each) to all the LPs that need them. There are over 200 new applicants that will not be licensed to make clones, so they will need to buy them repeadly. Let's just say 10% buy 2 million THC clones every year, that will mean they will do $40 million sales. Very easy to do, and this is not including the Clone Shipper, which you can $20 million.
Then you have the weed and extracts. They will be able to grow and produce another $60 million in cannabis and extracts (wholsaled at $4.20/gram - very ahead of the times compared to other LPs, meaning that they are prepared to sell it to retailers, Some LPs are spending so much money, that they will faiil if they compete with THC.
The testing facility is going to be used by many oother LPs after each harvest. That will generate a few more million dollars.
They are going to do at least $150 million in sales every year. ance weed is legalised
I can tell you the reason!
I shared the news yesterday about the upcoming cannabis ETF. I guess I wasn't the only one who noticed.
THC went up over 21% today from 78cents to 95cents. It will be doing 15% or more everyday for a while now. Investors took notice of the business plan, which includes making Kelowna, BC the legal MJ hub for Canada. They noticed they are licensed by Health Canada for every thing under the sun related to MMJ, which in itself holds a lot of value.
The SP is still very undervalued. The payoff is going to be huge in the long run. It's valued at $100 million. MJ is going to be a $22 Billion industry in cannabis sales alone. With all of their licenses, legalisation, R&D, Testing, They are worth at least $2 billion.
THC is going to be part of a cannabis ETF!
Here's the article! Great news for shareholders like myself!
Cannabis ETF Emerging AgroSphere Could Be First
February 16, 2017 at 3:34 pm
Breaking news by Alan Brochstein, CFA
ETF Managers Group Logo
ETF Managers Group, based in Summit, New Jersey, has filed an initial registration statement for what could be the first cannabis exchange-traded fund (ETF), the Emerging AgroSphere ETF. The proposed fund will be focused on medical cannabis and will not invest in any companies that are focused on serving the non-medical marijuana market in the United States, Canada or any other country unless and until such time as the production and sale of non-medical marijuana becomes legal in the United States, Canada or such other country, respectively.
The fund will replicate an index created by BE Asset Management to “track the performance of the exchange-listed common stock (or corresponding American Depositary Receipts (“ADRs”) or Global Depositary Receipts (“GDRs”)) of companies across the globe that (i) engage in lawful medical research intended to lead to the production of government approved prescription drugs which utilize natural or synthetic versions of the cannabidiol CBD and other cannabis based extracts, (ii) are involved in the production or sale of products which are legal derivatives of industrial hemp, or (iii) are involved in the supply chain of either category of company.”
The current sixty-nine constituents include: 22nd Century Group, Abattis Bioceuticals, Abbott Laboratories, Abbvie, Aero Grow Intl, Affinor Growers, Agritek Holdings, American Cannabis Company, Americann, Aphria, Arrow Electronics, Aurora Cannabis, Axim Biotechnologies, Beleave, Cannabics Pharmaceuticals, Cannabis Sativa, Cannabis Science, Cannabix Technologies, Cannagrow Holdings, Canopy Growth, Cara Therapeutics, Cree, CV Sciences, Easton Pharmaceuticals, Eco Science Solutions, Emblem, Emerald Health Therapeutics, General Cannabis, Golden Leaf Holdings, Green Cures & Botanical Distribution, Greengro Technologies, Growblox Sciences, GW Pharmaceuticals, Heliospectra, Hemp Inc, ICC International Cannabis, Inmed Pharmaceuticals, Insys Therapeutics, Kaya Holdings, Kush Bottles, Maple Leaf Green World, Marapharm Ventures, Marijuana Company Of America, Massroots, mCig, Medical Marijuana Inc, Medicine Man Technologies, Mentor Capital, Naturally Splendid Enterprises, New Colombia Resources, Novus Acquisition & Development, Nutritional High, Organigram, OWC Pharmaceutical, Pharmacan Capital, Pharmacyte Biotech, Rocky Mountain High Brands, Scotts Miracle-Gro, Signal Bay, Supreme Pharmaceuticals, Surna, Terra Tech, Tetra Bio-Pharma, THC Biomed, Trailblazer Resources, United Cannabis Corp, Veritas Pharma, Vodis Pharmaceuticals and Zynerba Pharmaceuticals.
Here is the performance of the index over the past year:
WEED Index 021617
New Cannabis Ventures will provide an update in the future regarding the status of the fund and an assessment of the underlying index and the cost structure. Until then, let us know what you think of the idea in our LinkedIn group, Cannabis Investors & Entrepreneurs.
Before this cannabis stock news is here, it's published to subscribers on 420 Investor.
Legalisation is happening everyone.
This is an opportunity to buy very low and sell very high with extremely low risk.
here's a Press Release from the Government:
Parliamentary Secretary Bill Blair launches tour to meet with Canadians to discuss cannabis legalization and regulation
News Release
From Department of Justice Canada
February 16, 2017 - Toronto, ON - Department of Justice Canada
Bill Blair, Parliamentary Secretary to the Minister of Justice and Attorney General of Canada Jody Wilson-Raybould, has started a cross-country tour to discuss the legalization and regulation of cannabis. Mr. Blair will be meeting with Canadians and various stakeholders on the government’s commitment to legalizing, strictly regulating and restricting access to cannabis.
The Government has committed to legalizing, regulating and restricting access to cannabis to keep it out of the hands of children and the profits out of the hands of criminals. The Government’s goal, with input from Canadians, is to better control access to cannabis, and put in place appropriate safeguards for its production and sale. These engagement sessions conducted by Mr. Blair will help further inform the Government’s work going forward.
Quotes
“I look forward to meeting with Canadians from across the country to hear their perspectives on regulating access to legal cannabis. We know that the current system of prohibition through the criminal justice system is not protecting the health and safety of Canadians, especially our young people. These meetings, along with the work of the Task Force on Cannabis Legalization and Regulation and the online consultations, will help inform the development of legislation to be introduced in Parliament this spring.”
Bill Blair, M.P.
Parliamentary Secretary to the Minister of Justice and Attorney General of Canada
Quick Facts
On December 13, 2016, the Government of Canada received the report from the Task Force on Cannabis Legalization and Regulation
The Government of Canada committed to introducing legislation for cannabis legalization in spring 2017
Associated Links
Task Force report for the Legalization and Regulation of Cannabis in Canada
Legalization and Regulation of Cannabis
Contacts
For more information, media may contact:
David Taylor
Office of the Minister of Justice
613-992-4621
Media Relations
Department of Justice Canada
613-957-4207
media@justice.gc.ca
Follow Department of Justice Canada on Twitter (@JusticeCanadaEn), join us on Facebook or visit our YouTube channel. Follow Minister Wilson-Raybould on Twitter (@MinJusticeEn).
Search for related information by keyword: Drug laws | Department of Justice Canada | Canada | Justice | general public | news releases | Hon. Jody Wilson-Raybould
Interest in growing cannabis creating backlog in Health Canada program
As of Feb 9, there are 2,554 individuals allowed to grow their own cannabis or designate someone to do so, with average processing time being about 7 weeks
SHARE THIS ARTICLE
Facebook
Twitter
LinkedIn 20
Google
Email
By David Brown
February 14, 2017
Health Canada’s new program that allows for authorized patients to grow their own cannabis for medical purposes is seeing a growing interest from Canadians.
André Gagnon, Media Relations Officer for Health Canada, told Lift in an update today that as of February 9th of this year, there are 2,554 individuals with an active Health Canada registration to produce cannabis for their own medical purposes or to designate someone to produce it for them.
According to Gagnon, the average processing time of individual registrations is currently about seven weeks, and variations in processing time from person to person can be caused “by a number of factors including the completeness of the information submitted, the need to verify certain information contained in the application, or the volume of applications received.”
“Health Canada is committed to ensuring that Canadians authorized to use medical cannabis have safe and reliable access to the product,” says Gagnon, “and the Department is processing these applications as quickly as possible to ensure they are approved promptly.”
The new program, introduced in August of last year, once again introduced legislation that allows patients who register with Health Canada to grow a limited number of plants for their own purpose, or to designate an authorized grower to do so for them. Health Canada had formerly allowed home production under the MMAR program, but halted new applications with the introduction of the MMPR in 2014.
A court challenge of this move created an injunction for many who were authorized to grow under the old system, and eventually resulted in a court case that essentially forced the government to re-introduce home production rules.
When the program was first introduced, some patients reported on social media that they received their completed paperwork back within a matter of weeks. Since then, more and more reports from patients indicate wait times are now a matter of months, not weeks. With a current average processing time of about seven weeks and early applications initially taking only a few weeks, one can conclude that current applications are taking longer than the average of seven weeks.
A patient who receives authorization from Health Canada to grow their own cannabis or to designate a grower for them can then purchase ‘starting material’ in the form of clones or seeds from a handful of licensed producers currently making them available. Once a licensed producer is chosen as a source of starting materials, the same registration can be used to purchase dried cannabis in the interim period while the patient waits for their crop to be ready.
Featured image via Brad Martin.
I love this stock, but it hasn't been performing as well as it should right now. The problem here is that there hasn't been a lot of volume moving, because everybody is holding for the something big to happen, predictably the Government's proposed legislation to legalise cannabis, and legalisation itself. That's when the sp will shoot upwards, and volume will be moving. Because of the lack of clarity on the timing of these things, a lot of investors are sitting on the sidelines waiting for things to happen before they act, like sheep they are, while predictable profits are staring them in the face. Savy investors look at business plans, pay attention to the news, and can easily see the obvious.
Here are the facts:
1. The Government of Canada is going to introduce legislation to legalise cannabis. Predictably, THC and every MMJ sp is going to shoot upwards, then hold steady, until 6 months before the proposed legalisation date, where is will steadily move upwards. It's very predictable, and there are only handful of times throughout the history of stock exchanges that things have been so predictable.
2. Cannabis will be legalised for recreational use in Canada, and will fall under a production regulatory regime headed by Health Canada.
3. The demand for cannabis is going to huge, the industry will be worth more than $22 BILLION every year.
THC Biomed has set itself up to becoming an integral part of meeting the public's demand for cannabis products. They are going to supply the hundreds of future LPs with clones; they are going to be testing hundreds of LPs harvests; they are going to supply a lot of cannabis products to the public, and their R&D is going to generate a lot of revenue.
They have a license for everything related to MMJ. Because of this, they are going to have many clients in their consulting services.
So yes, this is a undervalued stock. Should be selling for at least double right now, but people are sheep, and they will be herded in eventually. If you are not a sheep, buy this stock. It's selling for cheap, so you are getting a great deal.
I agree!
This HC release is good news for THC, as they will be using their their testing facility for some of the random tests, since there are not many facilities that test cannabis.
OTTAWA, Feb. 7, 2017 /CNW/ - Recently, two licensed producers of cannabis for medical purposes undertook voluntary recalls of cannabis products that contained low levels of prohibited pest control products (myclobutanil/bifenazate/pyrethrins). Under the Access to Cannabis for Medical Purposes Regulations (ACMPR), licensed producers are permitted to use only the 13 pest control products that are currently approved for use on cannabis under the Pest Control Products Act (PCPA).
In response to these events, Health Canada announced today that it will begin conducting random testing of medical cannabis products produced by licensed producers, to provide added assurance to Canadians that they are receiving safe, quality-controlled product. Health Canada will test these products to ensure that only authorized pest control products are used during the production of medical cannabis.
When any health and safety issue is found with a medical cannabis product, the first priority for Health Canada and the licensed producer is to protect the health and safety of clients by ensuring that they are informed and that the affected product is recalled. Following a recall, an investigation is carried out, and corrective actions are taken. This process was followed in both recalls mentioned above.
Health Canada is satisfied with the outreach to affected clients by the licenced producers. Corrective actions have been implemented by both companies, including an expanded testing regime that covers myclobutanil and other pest control products.
The Department will be providing additional compliance education and information to licensed producers to support their efforts to strengthen controls and safeguards to reduce the risk of the use of unauthorized pest control products. This will include communicating with all licensed producers to remind them of their obligations under the ACMPR and the PCPA.
The expanded product testing program will further enhance the Department's existing regime of regular unannounced inspections of licensed producer facilities, as well as the controls in place by licensed producers. Health Canada is committed to continuously improving on safety practices even though existing programs demonstrate effectiveness in identifying issues of non-compliance.
Health Canada remains committed to working closely with the 38 licensed producers to ensure that Canadians can have full confidence in their source of safe, quality-controlled cannabis for medical purposes.
I like how the sp is low right now. I'll admit to buying at a higher sp, but I am not worried about these low numbers. I also bought some at 77 cents, which is a great deal.
Here are some of the factors I consider. MMJ is at its infancy, and while it's at its infancy the legal recreational MJ market has not yet opened in Canada, but it is coming relatively soon. THC has positioned itself to to becoming a major supplier to MJ producers while also able to compete in the retail/wholesale market. They are the the only MMJ producer that is licensed for everything. Those licenses alone are worth so much.
I like that they have more than 30 strains of MJ, and they have the license clones. There are so many more applicants (more than 100) that are going to need their clones, need their testing facility, their extract services, and a whole lot more. The consumer market will know their limited product, but demand will require that they expand their facility to produce more cannabis.
THC has a solid future, don't let the sp fool you. It's cool now because there's a waiting game played by investors, which is causing the sp to be low and not a lot of volume moving either. When the government announces their legislation, this and most MMJ stocks will sky rocket in price. Savy investors will look at THC and see the true value and invest.
I just bought some at 77 cents to make a quick buck. I know it will be back up at 90-95 cents pretty soon in the next couple of weeks. The shares I bought previously are going to remain for the long, when recreational cannabis is legalised. It should be selling for at least $5 then.
The truth is, most MMJ stocks if not all are going to perform very well. I just think that THC will perform even better.
I think so.
I really like this though. Pretty obvious what they want to do with the clones though by getting other LPs to buy a lot of them. We should see the SP turn upwards prety soon.
Here's a report they posted today! I love it!
THC BioMed Begins Shipping Live Cannabis Plants across Canada to ACMPR Registered Patients and Announces Wholesale Genetic Pricing
THC BioMed Intl Ltd. (“THC” or the “Company”) (CSE: THC) (CSE: THC.CN) (CNSX: THC) (OTCQB: THCBF) (FRANKFURT: TFHC) is pleased to announce that it has begun shipping live cannabis plants to patients registered under the ACMPR.
On Monday, December 19, 2016, Health Canada granted THC an amendment to its license to allow THC to sell “Starting Materials”, meaning marihuana plants to legally authorized patients under the ACMPR.
We are very excited to begin shipping live Cannabis Plants to registered persons under the ACMPR. We have priced our starting material (“Clones”) at $20 per Clone, plus packaging and shipping. THC currently has 29 strains in stock. Please visit thcbiomed.com for information and ordering.
THC BioMed has structured its pricing to reflect its mandate of providing patients with accessibility to medicinal cannabis.
We are pleased to announce that we now offer genetics for sale to licensed producers under the ACMPR. With the increase in new licenses being granted by Health Canada we have initiated a service to provide newly licensed producers with the genetics they require to start production. THC also intends to participate in a genetic exchange service that would enable producers to exchange strains with THC Biomed. This would increase our genetic bank while giving producers the ability to increase their strain supply. THC also offers consulting services to new and aspiring licensed producers to assist them in achieving their applicable licensing requirements.
We are pleased to report the successful importation of the newly designed Clone Shipper 3.0 containers. THC has now used these containers to ship live cannabis plants across Canada. We believe that we are one of the first entities in Canada to ship live cannabis plants.
THC continues to pursue the acquisition of Clone Shipper. Management believes that purchasing Clone Shipper would allow THC to penetrate the U.S. and international cannabis markets, while remaining in compliance with U.S. and international laws by not dealing with cannabis where it remains illegal.
Wholesale pricing to Licensed Producers.
Genetic Exchange service
100 clones any strain. $10,000
Pack of 3 seeds any strain $2,500
Clone Shipper 3.0 $12.99
THC has begun increasing our production space and will take over two additional property Units adjacent to its current facility. This will increase THC’s footprint to 16,000 square feet.
THC will continue to protect shareholder value by using its existing infrastructure to ensure swift delivery of products to registered patients. THC will continue to expand our own assets in response to market demands. Management has determined that THC has sufficient infrastructure in place to cater to current patient demand.
About THC:
THC is licensed under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”) for the cultivation, production and sale of cannabis for medical purposes in the form of dried or fresh product, oil and starting materials. THC also conducts research & development of the products and services related to cannabis for medical purposes. Authorized purchasers can make product orders through www.thcbiomed.com.
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. Forward-looking information in this press release includes that (a) THC will provide newly licensed producers with genetics; (b) THC will participate in a genetic exchange service that would enable producers to exchange strains with THC Biomed; (c) THC will acquire Clone Shipper; (d) THC will penetrate the U.S. and the international cannabis markets, while remaining in compliance with U.S. and international laws; (e) THC will continue to protect shareholder value by using its existing infrastructure and ensure swift delivery of products to registered patients and expand its assets in response to market demands; and, (f) THC will take over two additional property units adjacent to its current facility, increasing THC’s footprint to 16,000 square feet. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CONTACT INFORMATION
President and CEO:
John Miller
THC Biomed Intl Ltd.
T: 1-844-THCMEDS
E: info@thcbiomed.com
I tried to link the page, I think it expired...
Finally! Volume moving! SP dropped a bit, but the good news is that there was a lot of volume moved in the last couple of days. That should boost the price up IMO.
Even better news:
Here's their financial report released today:
http://www.stockwatch.com/Quote/Detail.aspx?symbol=THC®ion=C
That is good news.
I personally really like this:
http://thcbiomed.com/thc-biomed-releases-packaging-design-sets-pricing-for-its-29-strains-at-4-20-gram/
$4.20/gram is cheaper than the black market and all the other LPs. On top of that they have 29 strains to chose from. I think that at that price they are going to have a huge share of the the market. This could potentially put the other LPs out of business who cannot compete with THC.
Hi everyone. I am new at investing and I want to invest in Cannabis.
I have done some research, but I am looking for opinions.
I looked into THC Biomed. It seems like they have a lot going for them.
Is it fair to say that they will do well because:
a)They are selling to other producers who are reselling it to their patients.
b)They are soon going to sell directly to patients.
c)They have a lot of strains.
d)They are selling oil.
c)They have a testing facility for other producers.
e)They do research and development.
f)Clone Shipper
g)They can help people set up personal grows
It seems like they are well positioned to succeed in Canada's legalized market.
So I thought I would ask all of you how you feel about this stock.
Is it undervalued?
How much do you all think this stock will grow to when cannabis is legalised in Canada?
To me, this looks like a good one, but I'm a rookie! So I am a little nervous.
Looking forward to your responses.
When did they post this?
That was nice.
Now I want to to see the recommendations by the task force.
I am new, and I want to invest in Cannabis stocks. Though I would check this forum out.